{"id":"NCT04392154","sponsor":"Eli Lilly and Company","briefTitle":"Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)","officialTitle":"A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-15","primaryCompletion":"2024-07-19","completion":"2025-04-22","firstPosted":"2020-05-18","resultsPosted":"2025-08-03","lastUpdate":"2025-08-03"},"enrollment":1153,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"BIOLOGICAL","name":"Lebrikizumab","otherNames":["LY3650150","DRM06"]}],"arms":[{"label":"Lebrikizumab Q2W (Primary Treatment Period)","type":"EXPERIMENTAL"},{"label":"Lebrikizumab Q4W (Primary Treatment Period)","type":"EXPERIMENTAL"},{"label":"Open-Label Extension Addendum","type":"EXPERIMENTAL"}],"summary":"This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.","primaryOutcome":{"measure":"Percentage of Participants Discontinued From Study Treatment Due to Adverse Events","timeFrame":"Baseline to Week 100","effectByArm":[{"arm":"Lebrikizumab Q4W","deltaMin":2.1,"sd":null},{"arm":"Lebrikizumab Q2W","deltaMin":4.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":321,"countries":["United States","Australia","Bulgaria","Canada","Estonia","France","Germany","Latvia","Lithuania","Mexico","Poland","Singapore","South Korea","Spain","Taiwan","Ukraine"]},"refs":{"pmids":["40549127"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":141},"commonTop":["Covid-19","Nasopharyngitis","Dermatitis atopic","Upper respiratory tract infection","Conjunctivitis"]}}